Industry Radar
Exploring the latest in Industry Radar.
16 Biotechnology Trends for 2026: How to Stay Ahead
Discover 16 biotechnology trends that will shape 2026, including AI-driven drug discovery, decentralized clinical trials, sustainable biomanufacturing, and more. Stay ahead in life sciences.
Water Scarcity and Critical Mineral Traceability: New Market Signals for Biotech Innovation
Market intelligence reveals two trends—water resilience and critical mineral traceability—that are creating new opportunities and risks for biotechnology. Learn how biotech can respond.
An analysis of the Deloitte 2024 global insurance outlook and its impact on the biotechnology sector, including risk management challenges and opportunities for innovation.
ESG and Sustainability Advisory Market: A Strategic Imperative for Biotechnology and Life Sciences
The global ESG and sustainability advisory market is projected to reach $85.8 billion by 2035, reshaping how biotechnology companies manage risk, attract capital, and build resilient, sustainable operations.
Biotechnology Consulting Services Market Insights Highlight Segment Expansion and Market Leadership
The biotechnology consulting services market is projected to reach $12.4 billion by 2030, driven by AI integration, regulatory complexity, and demand for specialized expertise in drug development and commercialization.
Austmine urges Treasury to recognise METS innovation
Austmine calls on the Australian government to ensure the proposed Innovative Business Capital Gains Tax Concession recognizes the unique innovation pathways of the mining equipment, technology and services (METS) sector.
An analysis of the environmental and construction professional liability insurance market in mid-2026, covering key lines such as CPL, PLL, AEPL, and more, with insights on rates, capacity, and emerging risks like PFAS.
Mapping the Future: 7 Markets Reveal the Infrastructure of the Next Decade (2026-2033)
Cognitive Search Service Market 2025-2032: Cloud-Driven Growth, Regional Shifts, and the Unfolding Knowledge Economy
Why And How To Use a Trend Radar for Innovation, Market Monitoring, and Strategic Planning
Biotech Industry Trends in 2024: How AI, Gene Editing, Big Data, Precision Medicine, and Cell Therapies Are Reshaping eQMS
Decoding YouTube’s Legal Architecture: What the Footer Links Reveal About Platform Governance and Future Trends
Biotech Industry Trends: How Biotechnology is Transforming Health, Fashion, and the Planet
5 Biotech Trends to Watch in 2026: A Fragile Rebound, China’s Rise, and the AI Revolution
Biotech Industry Trends 2026: Navigating Patent Cliff, Obesity Platform Era, and AI Regulatory Shifts
Beyond the Dip: How AI and Precision Medicine Are Reshaping Biopharma's Cost Crisis in 2025
Regeneron’s Hearing Loss Gene Therapy: FDA Approval and the Hidden Value of Priority Review Vouchers
Navigating the Unsayable: How Information Architecture Handles Content Rejection in Automated Systems
Tolebrutinib's Regulatory Crossroads: Why Europe and the FDA See Multiple Sclerosis Differently
How AI Partnerships and Clinical Data Are Reshaping the Pharma Landscape: Merck, Google, and Roche Take Center Stage
The New Public Health Paradox: How Moderna’s mRNA Bird Flu Trial Could Redefine Pandemic Funding Models
BioAge’s NLRP3 Inhibitor Data: Mapping the Competitive Landscape and Economic Logic Behind the ‘Best-in-Class’ Claim
Merck’s Welireg Phase 3 Setback: What It Means for the Future of First-Line Kidney Cancer Therapy
Beyond Survival: How RMC-6236's KRAS G12D Breakthrough Reshapes the Pancreatic Cancer Market and Investment Landscape
Allogene's Off-the-Shelf CAR-T Data: A Turning Point for Manufacturing and Access in Lymphoma?
Beyond the Headlines: How ACIP Rule Changes and Protein Degrader R&D Reveal a Biopharma Industry at a Crossroads
Beyond the Megaround: How Oricell's Pre-IPO Bet Exposes the Next Frontier in the CAR-T Arms Race
Beyond the IPO: How Avalyn Pharma's Inhaled IPF Strategy Challenges a $4 Billion Market
Beyond the Headlines: The Hidden Market Logic Behind Pharma's Pricing, Trials & Unlikely Alliances
Jeito Capital's $1.2B Bet: Decoding the Late-Stage Biopharma Investment Thesis in a Volatile Market
Beyond the Boardroom Battle: The High-Stakes Proxy Fight Signaling a Biotech Investment Paradigm Shift
Beyond the $137M: How Sidewinder's ADC Tech Bet Reflects a Shifting Biotech Investment Thesis
The $787M Bet: How Earendil Labs' AI Biologics Deal Signals a New Pharma Investment Era
Beyond the $2B Deal: How Novartis' Acquisition of Inavolisib Signals a Strategic Shift in Precision Oncology
Beyond Genetics: How Rhythm Pharma's FDA Win Redefines the Obesity Market and Brain-Body Pathways
Beyond the Dose: How Novo Nordisk's Priority Voucher Strategy Reveals Pharma's New Playbook
Beyond the Mutation: How Pfizer's Talzenna Data Redefines Prostate Cancer Treatment Economics
Beyond the 20% Surge: How Apogee's Infrequent-Dosing Eczema Drug Could Reshape the Biopharma Business Model
Beyond the Headline: AstraZeneca's Shanghai Cell Therapy Bet and China's Biotech Power Play
FDA's Divergent Decisions: How Clinical Trial Data Quality is Reshaping Biotech Investment
Beyond the $69M: How Excalipoint's T-Cell Engagers Signal China's Strategic Shift in Biotech
A comprehensive analysis of merger and acquisition trends, licensing deals, and strategic collaborations shaping the biotech landscape in the fourth quarter of 2024.